Inositec, a pioneer in the development of life-saving small molecule drugs based on inositol hexaphosphate (IP6), announced today the closing of a CHF1.4 million (US$1.42 million) seed financing. Investors participating in the round included VI Partners via the Venture Incubator fund and Zürcher Kantonalbank. The proceeds will be used to progress a drug candidate from Inositec’s proprietary Inositune™ platform through preclinical proof-of-concept.
“Inositol hexaphosphate is a naturally occurring substance that acts as a messenger in cells and is involved in multiple biochemical pathways,” explained Dr. Mattias Ivarrson, CEO of Inositec. “Using this molecule as a starting point, we have created a new class of compounds that have been specifically designed to address various therapy areas. Our programs address significant medical needs in vascular calcification and Clostridium difficile infection. This financing will enable us to advance a lead candidate from one of these programs through preclinical evaluation and ready for progression to clinical studies.”
In conjunction with the financing. Michael Wacker, PhD, was appointed as Chairman of the Board of Directors. Dr. Wacker is a serial entrepreneur, co-founding several companies including GlycoVaxyn and Limmatech. He also coaches start-ups in Switzerland for CTI, the governmental commission of technology and innovation.
“Inositec has made tremendous progress since its founding in December last year. I have been very impressed by the broadly applicable technology as well as the dedicated manner in which the team is building the company,” stated Dr. Wacker. “Inositec’s compounds have significant promise in multiple therapeutic areas where there is a great need for new, effective medicines. I look forward to working alongside the management team to help deliver on this huge potential.”
Inositec is pioneering the development of life-saving small molecule drugs based on inositol phosphate, a natural facilitator of diverse cellular functions. Using its broadly applicable Inositune™ technology to adjust the chemical and physical properties of inositol phosphate analogs, Inositec is developing a novel class of drugs initially focusing on two areas of high-unmet medical need: calcification disorders and Clostridium difficile infection. Inositec was founded in December 2015 based on the award-winning research of Dr Mattias Ivarsson, Prof Jean-Christophe Leroux and Prof Bastien Castagner at ETH Zurich, Switzerland. Further information can be found at www.inositec.com.
About VI Partners
VI Partners is a Swiss venture capital firm and advisor to Venture Incubator (VI). VI was established by McKinsey & Company and the Swiss Federal Institute of Technology in Zürich (ETHZ) in 2001. VI is an evergreen fund with a paid in capital of CHF 101m. The investors are 10 Swiss blue-chip companies from industry and finance. For further information visit www.vipartners.ch.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161026006522/en/Business Wire
Last updated on: 27/10/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.